Skip to Main Content

ATLANTA — If you want to avoid shingles — a condition that comes with a painful rash — there is a vaccine available. But studies have shown that protection generated by the vaccine declines quickly.

A new vaccine, however, is being considered for approval, and if and when the Food and Drug Administration gives it the green light, its may hit the market with a highly desirably preferential rating from an influential panel of vaccine experts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • ““A preferential recommendation will make a difference here,” Bresnitz told the committee. “Let the market determine what happens here.”

    Translation: Let marketing, not the data, decide.

Comments are closed.